Aurobindo Pharma — Latest News

Every announcement Aurobindo Pharma has filed with the exchanges that we have reported, newest first. Each story links the original filing.

NSE: AUROPHARMA BSE: 524804 Pharmaceuticals & Biotechnology 2 stories

Price

₹1679.8

Market Cap

₹97,563.05 Cr

Revenue TTM

₹34,935.29 Cr

P/E (TTM)

24.76×

Sector 49.41×

Reference data from Trendlyne, as of the most recent story. Not a valuation or a recommendation.

Regulatory Approval · 1 Product Launched · 1
Regulatory Approval

Aurobindo Pharma Secures USFDA Approval for First MDI Product in US$301M Market

Aurobindo Pharma receives USFDA final approval for its first MDI product, targeting a US$301 million market. The approval covers Beclomethasone Inhal…

Product Launched

Aurobindo Pharma Subsidiary Lannett Launches First US Inhalation Product in $908M Market

Aurobindo Pharma subsidiary Lannett launches generic Advair Diskus in the US, marking its first inhalation product entry into the $908M respiratory m…

Track Aurobindo Pharma in real time

ALFA Finder watches NSE & BSE filings 24/7 and alerts you the moment Aurobindo Pharma files something material.

Start Free — 15-day trial